Teva annonce des résultats positifs pour un médicament de traitement cutané
La société israélienne a rapporté dans l'étude que les patients ont montré des améliorations de la pigmentation cutanée avec le vitiligo.
Évaluation
Teva's positive vitiligo drug results could open a new therapeutic pathway for a condition with limited treatment options. The improvements in skin pigmentation observed in the study are a meaningful clinical signal, but the durability and safety profile will determine regulatory and commercial potential. Investors will watch for the full data presentation and the company's next steps toward a pivotal trial.